Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. [electronic resource]
Producer: 20080221Description: 2802-8 p. digitalISSN:- 1600-6135
- Adolescent
- Adult
- Aged
- Alemtuzumab
- Antibodies, Anti-Idiotypic -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm -- therapeutic use
- Antigens, CD -- immunology
- Antigens, Neoplasm -- immunology
- Biopsy
- Bronchiolitis Obliterans -- drug therapy
- CD4-Positive T-Lymphocytes -- drug effects
- CD52 Antigen
- Female
- Forced Expiratory Volume -- physiology
- Glycoproteins -- immunology
- Graft Rejection -- drug therapy
- Humans
- Kaplan-Meier Estimate
- Lung -- pathology
- Lung Transplantation -- adverse effects
- Male
- Middle Aged
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.